US · Healthcare · Health Information Services
EPS came in at -0.35 against a street estimate of -0.41 — a beat of 14.6%.
Analysts rate Tempus AI, Inc. Class A Common Stock a buy (6 buy, 6 hold, 0 sell out of 12) with an average price target of $67.59.
CONFIDENT TEM delivered 22% revenue growth to $382.5M, raised FY26 guidance to $1.595–1.605B (+25% YoY). FDA approval of xT CDx unlocks ~$85M ASP uplift in 2027; xF liquid biopsy in FDA review with $550 additional ASP expected. Personalis MRD acquisition announced; data/apps segment grew 28% YoY. Q2 2026 Call did not segment revenue by geography. Analysts pressed xF pricing evolution (Rogers clarified Guardant comp justifies higher ADLT), Personalis termination risk (Lefkofsky cited cash/stock levers and deal attractiveness to Personalis), and data deal economics (confirmed no revenue recognition shift, only platform stickiness). Management expressed high confidence in close and data momentum. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| ARK Investment Management LLC | 5.29% |
| BlackRock Inc | 4.94% |
| Baillie Gifford & Co Limited. | 4.51% |
| SoftBank Group Corp | 2.98% |
| JPMorgan Chase & Co | 2.72% |
| Vanguard Capital Management, LLC | 2.71% |
| Vanguard Portfolio Management, LLC | 2.58% |
| Amova Asset Management Americas, Inc | 2.38% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 TEMPUS AI, INC. — 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Total net revenue (6 months ended June 30, 2026): $730.6 million vs. $570.4 m | 2026-07-30 |
| Results announced · Q3 2026 TEMPUS AI, INC. – Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Total revenue: $382.5 million (Q2 2026), up 22% year-over-year • Full-year 2026 revenue | 2026-07-30 |
| Material agreement · Q3 2026 TEMPUS AI, INC. — MERGER AGREEMENT WITH PERSONALIS, INC. Form 8-K Filed July 20, 2026 --- HEADLINE NUMBERS • Merger Consideration (Cash Component): | 2026-07-20 |
| Reg FD disclosure · Q3 2026 TEMPUS AI, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Announcement Date: July 20, 2026 • Company: Tempus AI, Inc. (Nevada corporation, ticker: TEM, | 2026-07-20 |
| Shareholder vote results · Q2 2026 TEMPUS AI, INC. - 8-K SUMMARY (MAY 21, 2026) HEADLINE NUMBERS • Annual Meeting of Stockholders held on May 21, 2026 • Company has dual-class share s | 2026-05-22 |
| Quarterly report · Q1 2026 TEMPUS AI, INC. – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Total Net Revenue (Q1 2026): $348.1 million, up 36% from $255.7 million in Q1 2025 • | 2026-05-05 |
| Proxy statement · Q2 2026 TEMPUS AI, INC. – 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect nine directors to the Board, serving until t | 2026-04-07 |
| Annual report FY2025 TEMPUS AI, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market Capitalization: $11.0 billion as of June 30, 2025 (stock price $63.54/ | 2026-02-24 |
Readable in the app.
| Announcement | Date |
|---|---|
| Revenue guidance raised to $1.595-$1.605 billion for 2026 Tempus AI reported strong Q2 2026 results with 22% year-over-year revenue growth to $382.5 million. Key highlights include accelerating oncology diagnostics volume growth (31% YoY), strong d | 2026-07-30 |
| Proposed transaction and merger agreement between two companies Tempus and Personalis announced a proposed merger. This 8-K filing is primarily a forward-looking statements disclaimer, outlining risks and uncertainties rather than disclosing deal specifi | 2026-07-20 |
| Entered into merger agreement with Personalis, Inc. Tempus AI announced on July 20, 2026 that it has agreed to acquire Personalis, Inc. in an all-stock or mixed stock-and-cash merger transaction. Under the deal, Personalis shareholders will r | 2026-07-20 |
| Q1 2026 results; raised 2026 revenue guidance to $1.59-$1.60 billion Tempus AI reported strong Q1 2026 results with revenue of $348.1 million, up 36% year-over-year. Diagnostics revenue grew 35% to $261.1 million, driven by 28% oncology volume growth and exce | 2026-05-05 |
| 2026 revenue guidance of $1.59B and Adjusted EBITDA of $65M provided Tempus AI reported strong 2025 results with revenue of $1.3 billion, up 83% year-over-year. The diagnostics division drove growth with $955.4 million in revenue (up 111.5%), powered by oncol | 2026-02-24 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tempus AI, Inc. Class A Common Stock — free to start.
Google PlayApp StoreData updated 2026-09-18.